Loop Energy Enters Agreement with METTEM-M to Build Hydrogen Electric Powertrains for Commercial Vehicles in Russia; Transit Bus on Display at COMTRANS 2021
Loop Energy (TSX: LPEN), a developer and manufacturer of hydrogen fuel cell-based solutions, announces their partnership with METTEM-M Ltd., a developer of vehicle control systems and systems integrator, to provide hydrogen electric powertrain solutions to commercial vehicle OEMs across Russia, the Commonwealth of Independent States (CIS), and greater Europe. The companies’ first joint project — a hydrogen electric transit bus for GAZ Group, a leading global commercial vehicle OEM provider — is presently on display at the International Commercial Vehicle Show 2021 (COMTRANS) in Moscow, Russia. The 12-meter passenger bus vehicle is expected to enter regular city transport service in Moscow, in early 2022, after completing customary road testing and vehicle level certification requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005445/en/
(Photo: Business Wire)
Under this agreement, METTEM will use Loop’s eFlow™ powered fuel cell modules to develop and supply hydrogen electric subsystems, powertrains, and complete vehicle solutions for a variety of applications including transit buses, logistics vehicles, and rail transport.
The hydrogen electric transit bus, currently showcased by its OEM at COMTRANS 2021, marks the first commercial achievement between Loop Energy and METTEM. The vehicle’s hydrogen electric control system was developed by METTEM under the contract with GAZ Group — a leading manufacturer of light commercial and medium-duty vehicles, buses, powertrain and automotive components, and special-use vehicles headquartered in Russia. The solution is using GAZ Group’s existing battery electric passenger bus platform, Loop Energy’s high efficiency fuel cell modules, and METTEM’s fully integrated hydrogen electric fuel cell system.
“Partnering with Loop was a natural next step for METTEM as we look to supply our OEM customers with mobility solutions that meet the growing demand in Russia and beyond for electric and hydrogen fuel cell vehicles over the next decade,” said Jan Drewitz, CEO of METTEM. “With Loop’s innovative fuel cell modules and our extensive powertrain and vehicle integration expertise, we foresee hydrogen electric solutions, and the benefits of extended range, peak power performance, and fuel efficiency, becoming the gold standard in the commercial vehicle market.”
“Collaborating with METTEM is a key milestone for both the adoption of hydrogen electric solutions for commercial vehicles, as well as expanding Loop’s footprint in both Russian and greater European markets,” said George Rubin, Chief Commercial Officer of Loop Energy. “METTEM’s market knowledge and technical expertise bring an invaluable contribution to this partnership. We are seeing a steady demand for clean energy alternatives across the globe and are eager to work with a leading player in the commercial vehicle industry to provide sustainable solutions.”
About METTEM
METTEM-M, Ltd. is a company of the METTEM TRANSPORT Group. It is also a Russian enterprise that develops, integrates, and produces in series digital E/E control systems, onboard equipment for navigation and other purposes, as well as solutions for both vehicle manufacturers (buses, trucks, special vehicles, passenger cars) and transport operators. METTEM TRANSPORT Group is focused extremely on innovations to improve its products continuously and release new items. Cooperation with Loop Energy will make it possible to implement projects in a trendy area of hydrogen transportation. Applying its experience and competences, METTEM-M is designing hydrogen vehicles as effective and safe for use as possible. https://mettem-m.ru/
About Loop Energy Inc.
Loop Energy is a leading designer and manufacturer of fuel cell systems targeted for the electrification of commercial vehicles, including, light commercial vehicles, transit buses and medium and heavy-duty trucks. Loop’s products feature the Company’s proprietary eFlow™ technology in the fuel cell stack’s bipolar plates. eFlow™ was designed to enable commercial customers to achieve performance maximization and cost minimization. Loop works with OEMs and major vehicle sub-system suppliers to enable the production of hydrogen fuel cell electric vehicles. For more information about how Loop is driving towards a zero-emissions future, visit www.loopenergy.com.
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflect management’s current expectations and projections regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control and could cause actual results and events to vary materially from those that are disclosed, or implied, by such forward-looking information. Such risks and uncertainties include, but are not limited to, the ability of the Company to execute on its strategy and the factors discussed under “Risk Factors” in the Company’s Annual Information Form dated March 30, 2021. Loop disclaims any obligation to update these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005445/en/
Contact information
Loop Energy Media Contact: Ashley Eisner | Tel: +1.212.697.2600 | aeisner@gscommunications.com
Loop Energy Business Contact: George Rubin | Tel: +1.604.828.8185 | grubin@loopenergy.com
METTEM Business Contact: Yuri Yanovich | Tel: +7.916.412.18.33 | yv.yanovich@mettem-m.ru
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com